Jiangxi Fushine Pharmaceutical Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 0.02%

Jiangxi Fushine Pharmaceutical Co Ltd (300497) has an Asset Resilience Ratio of 0.02% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 300497 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥816.50K
≈ $119.48K USD Cash + Short-term Investments

Total Assets

CN¥4.48 Billion
≈ $655.46 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2011–2025)

This chart shows how Jiangxi Fushine Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Jiangxi Fushine Pharmaceutical Co Ltd.

Liquid Assets Composition Over Time

This chart breaks down Jiangxi Fushine Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 300497 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥816.50K 0.02%
Total Liquid Assets CN¥816.50K 0.02%

Asset Resilience Insights

  • Limited Liquidity: Jiangxi Fushine Pharmaceutical Co Ltd maintains only 0.02% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Jiangxi Fushine Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jiangxi Fushine Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
ALK-Abelló A/S
CO:ALK-B
Biotechnology 0.98%
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
Biotechnology 6.89%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
BB Biotech AG
SW:BION
Biotechnology 92.97%
Soleno Therapeutics Inc
NASDAQ:SLNO
Biotechnology 20.15%
Nanobiotix
NASDAQ:NBTX
Biotechnology 4.71%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590
Biotechnology 10.55%

Annual Asset Resilience Ratio for Jiangxi Fushine Pharmaceutical Co Ltd (2011–2025)

The table below shows the annual Asset Resilience Ratio data for Jiangxi Fushine Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.02% CN¥954.50K
≈ $139.67K
CN¥4.40 Billion
≈ $644.55 Million
-0.03pp
2024-12-31 0.05% CN¥2.19 Million
≈ $319.73K
CN¥4.54 Billion
≈ $663.89 Million
+0.00pp
2023-12-31 0.05% CN¥2.19 Million
≈ $319.73K
CN¥4.82 Billion
≈ $705.18 Million
-0.94pp
2022-12-31 0.98% CN¥49.74 Million
≈ $7.28 Million
CN¥5.06 Billion
≈ $740.41 Million
-2.24pp
2021-12-31 3.22% CN¥150.76 Million
≈ $22.06 Million
CN¥4.68 Billion
≈ $684.61 Million
+0.59pp
2020-12-31 2.64% CN¥106.68 Million
≈ $15.61 Million
CN¥4.05 Billion
≈ $592.01 Million
+2.97pp
2019-12-31 -0.33% CN¥-8.69 Million
≈ $-1.27 Million
CN¥2.60 Billion
≈ $379.85 Million
-0.17pp
2018-12-31 -0.17% CN¥-3.72 Million
≈ $-544.44K
CN¥2.20 Billion
≈ $321.41 Million
-0.18pp
2017-12-31 0.01% CN¥114.11K
≈ $16.70K
CN¥1.79 Billion
≈ $261.85 Million
-12.15pp
2016-12-31 12.16% CN¥170.00 Million
≈ $24.88 Million
CN¥1.40 Billion
≈ $204.63 Million
+12.15pp
2013-12-31 0.00% CN¥13.23K
≈ $1.94K
CN¥541.31 Million
≈ $79.21 Million
-0.02pp
2011-12-31 0.03% CN¥96.12K
≈ $14.07K
CN¥352.57 Million
≈ $51.59 Million
--
pp = percentage points

About Jiangxi Fushine Pharmaceutical Co Ltd

SHE:300497 China Biotechnology
Market Cap
$1.72 Billion
CN¥11.77 Billion CNY
Market Cap Rank
#6716 Global
#1368 in China
Share Price
CN¥21.86
Change (1 day)
-0.86%
52-Week Range
CN¥9.75 - CN¥23.34
All Time High
CN¥24.76
About

Jiangxi Fushine Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of APIs and pharmaceutical intermediates in China and internationally. It offers ß-lactamase inhibitors, carbapenem antibiotics, and antiviral drug intermediates; argatroban injection for the treatment of acute ischemic stroke; and doxycycline hydrochloride dispersi… Read more